Table 5 Concomitant drug treatment
| Â | Meta-analysis | DPV/DIVE patients with CKDa | ||||
|---|---|---|---|---|---|---|
|  | FIDELITY | Total | Total ACEi/ARB | RCT ( +) | RCT (-) | p-value |
|  | n = 13,026 | n = 65,168 | n = 28,359 | n = 12,322 | n = 16,037 | RCT + vs. - |
Statins, n (%) | 72.2 | 36.9 | 59.0 | 62.3 | 56.5 |  < 0.0001 |
Platelet aggregation inhibitors, n (%) | 56.0 | 9.8 | 15.1 | 15.3 | 14.9 | 0.3312 |
Antihypertensive drugs | Â | Â | Â | Â | Â | Â |
 ACEi, n (%) | 39.0 | 26.8 | 61.5 | 62.3 | 61.0 |  < 0.0001 |
 ARBs, n (%) | 60.9 | 16.7 | 38.5 | 37.8 | 39.0 | 0.0385 |
 MRAs, n (%) | n.a. / 0 | 4.6 | 7.7 | 8.1 | 7.5 | 0.0742 |
 Beta-blockers, n (%) | 49.9 | 36.3 | 61.0 | 60.6 | 61.2 | 0.3640 |
Diuretics | Â | Â | Â | Â | Â | Â |
 Loop diuretics | 21.5 | 14.1 | 23.5 | 22.0 | 24.7 |  < 0.0001 |
 Thiazide diuretics | 24.2 | 4.6 | 9.2 | 10.5 | 8.2 |  < 0.0001 |
 Calcium antagonists, n (%) | 56.5 | 20.3 | 37.6 | 40.3 | 35.5 |  < 0.0001 |
Glucose lowering therapies, n (%) | Â | Â | Â | Â | Â | Â |
 Insulin, n (%) | 58.6 | 58.9 | 63.6 | 63.0 | 64.1 | 0.0744 |
 Metformin, n (%) | 58.0 | 38.0 | 43.7 | 50.4 | 38.6 |  < 0.0001 |
 Acarbose, n (%) | 5.0 | 0.4 | 0.5 | 0.6 | 0.5 | 0.3312 |
 Sulfonylurea, n (%) | 26.0 | 5.2 | 5.5 | 5.9 | 5.2 | 0.0150 |
 DPP-4 inhibitors, n (%) | 25.2 | 25.8 | 28.4 | 28.2 | 28.7 | 0.4469 |
 GLP-1 agonists, n (%) | 7.2 | 6.4 | 8.4 | 9.7 | 7.3 |  < 0.0001 |
 SGLT2 inhibitors, n (%) | 6.7 | 8.0 | 10.0 | 12.4 | 8.2 |  < 0.0001 |